Additionally, the treatment of IGF-1 also enhanced the expression of EMT biomarkers, such as the expression of N-cadherin, MMP2 and Slug in a dose-dependent fashion, which indicated that IGF-1 has a regulatory effect on EMT of GC. The gene discussed is IGF1; the disease is gastric cancer.